GentiBio and Forge Biologics Announce Viral Vector Contract Development and GMP Manufacturing Partnership
Partnership to support GentiBio’s cell therapy pipeline with AAV process development, scale up and GMP manufacturing services
BOSTON & SEATTLE & COLUMBUS, Ohio--(BUSINESS WIRE)-- GentiBio, Inc., an emerging biotherapeutics company developing best-in-class engineered regulatory T cells programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases, and Forge Biologics, a cell and gene therapy-focused contract development and manufacturing organization (CDMO), announced a strategic development and manufacturing partnership today to advance GentiBio’s unique immune tolerance platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210715005550/en/
Forge will provide adeno-associated viral (AAV) vector process and analytical development, scale-up engineering and GMP manufacturing services for GentiBio’s engineered Tregs therapeutic candidates. The program will employ both Forge’s Blaze Vector™ production platform and HEK 293 Suspension Ignition Cells™ to facilitate GentiBio’s development process. All development and GMP activities will occur at The Hearth, Forge’s 175,000 ft2 gene therapy GMP production facility in Columbus, Ohio.
“We are thrilled to partner with Forge Biologics and their experienced team to further develop our lead engineered Treg program and take a critical step in advancing our therapies to patients in need,” said Andy Walker, Ph.D., co-founder and Chief Technology Officer of GentiBio. “Forge offers a broad array of services ranging from process development to GMP manufacturing, making them a strong partner for GentiBio’s cell therapies with capacity to support GentiBio as we advance programs through clinical development.”
Forge’s Hearth is the home of a state-of-the-art cGMP facility dedicated to AAV viral vector manufacturing and will host end-to-end manufacturing services to accelerate cell and gene therapy programs from preclinical through clinical and commercial stage manufacturing. Forge offers product and analytical development services, cGMP manufacturing and regulatory support services.
“Our team is excited to embark on this partnership with GentiBio to meet their viral vector manufacturing needs and help them advance to clinical trials,” said Timothy J. Miller, Ph.D., Chief Executive Officer, President, and Co-Founder of Forge. “Forge is committed to providing quality AAV manufacturing to all stages of program development, and this partnership highlights the Forge team’s capabilities to help innovators such as the GentiBio team on their path to success.”
GentiBio, Inc., is an emerging biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio’s proprietary autologous and allogeneic EngTregs platform integrates key complementary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overactivity and/or malfunctioning of the immune system. To learn more, visit https://www.gentibio.com
About Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea into reality. Forge has a 175,000 ft2 facility in Columbus, Ohio, The Hearth, to serve as their headquarters. The Hearth is the home of a custom-designed cGMP facility dedicated to AAV viral vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge is building on the theme of “Hope in Ohio” to accelerate the timelines of these transformative medicines for those who need them the most.
To learn more, visit www.forgebiologics.com
Media Inquiries, GentiBio:
Verge Scientific, Inc.
Media Inquiries, Forge Biologics:
Director of Communications and Community Development
Forge Biologics, Inc.
Vice President and Head of Business Development
Forge Biologics, Inc.
Vice President, Finance and Operations
Forge Biologics, Inc.
Source: GentiBio, Inc.